Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natalie Ives

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|March 4, 2011
Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's diseaseRebecca Stowe, Natalie Ives, Carl E Clarke, et al.
Lancet (London, England)|June 15, 2014
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial, Richard Gray, Natalie Ives, et al.
JAMA Internal Medicine|April 25, 2017
Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical TrialNicholas J Cowley, Andrew Owen, Sarah C Shiels, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 3, 2015
Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trialSunil Bhandari, Natalie Ives, Elizabeth A Brettell, et al.
JAMA Neurology|January 20, 2016
Physiotherapy and Occupational Therapy vs No Therapy in Mild to Moderate Parkinson Disease: A Randomized Clinical TrialCarl E Clarke, Smitaa Patel, Natalie Ives, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 7, 2021
Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's DiseaseEmma McIntosh, Seamus Kent, Alastair Gray, et al.
Pilot and Feasibility Studies|August 10, 2021
Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trialSarah Scobie, Sue Jowett, Tosin Lambe, et al.
The Lancet. Neurology|May 4, 2010
Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trialAdrian Williams, Steven Gill, Thelekat Varma, et al.
JAMA Neurology|December 28, 2021
Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical TrialRichard Gray, Smitaa Patel, Natalie Ives, et al.
Preventive Medicine|October 18, 2021
'Snacktivity™' to increase physical activity: Time to try something different?James P Sanders, Stuart J H Biddle, Kajal Gokal, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Movement Disorders : Official Journal of the Movement Disorder Society|March 4, 2011
Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's diseaseRebecca Stowe, Natalie Ives, Carl E Clarke, et al.
Lancet (London, England)|June 15, 2014
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial, Richard Gray, Natalie Ives, et al.
JAMA Internal Medicine|April 25, 2017
Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical TrialNicholas J Cowley, Andrew Owen, Sarah C Shiels, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 3, 2015
Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trialSunil Bhandari, Natalie Ives, Elizabeth A Brettell, et al.
JAMA Neurology|January 20, 2016
Physiotherapy and Occupational Therapy vs No Therapy in Mild to Moderate Parkinson Disease: A Randomized Clinical TrialCarl E Clarke, Smitaa Patel, Natalie Ives, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 7, 2021
Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's DiseaseEmma McIntosh, Seamus Kent, Alastair Gray, et al.
Pilot and Feasibility Studies|August 10, 2021
Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trialSarah Scobie, Sue Jowett, Tosin Lambe, et al.
The Lancet. Neurology|May 4, 2010
Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trialAdrian Williams, Steven Gill, Thelekat Varma, et al.
JAMA Neurology|December 28, 2021
Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical TrialRichard Gray, Smitaa Patel, Natalie Ives, et al.
Preventive Medicine|October 18, 2021
'Snacktivity™' to increase physical activity: Time to try something different?James P Sanders, Stuart J H Biddle, Kajal Gokal, et al.
Pageof 9